Search Results - "SETO, Takashi"

Alectinib versus crizotinib in patients with ALK -positive non-small-cell lung cancer (J-ALEX): an open-label, randomised phase 3 trial by Hida, Toyoaki, MD, Nokihara, Hiroshi, MD, Kondo, Masashi, MD, Kim, Young Hak, MD, Azuma, Koichi, MD, Seto, Takashi, MD, Takiguchi, Yuichi, Prof, Nishio, Makoto, MD, Yoshioka, Hiroshige, MD, Imamura, Fumio, MD, Hotta, Katsuyuki, Prof, Watanabe, Satoshi, MD, Goto, Koichi, MD, Satouchi, Miyako, MD, Kozuki, Toshiyuki, MD, Shukuya, Takehito, MD, Nakagawa, Kazuhiko, Prof, Mitsudomi, Tetsuya, Prof, Yamamoto, Nobuyuki, Prof, Asakawa, Takashi, PhD, Asabe, Ryoichi, MS, Tanaka, Tomohiro, MS, Tamura, Tomohide, Dr

“…Summary Background Alectinib, a potent, highly selective, CNS-active inhibitor of anaplastic lymphoma kinase (ALK), showed promising efficacy and tolerability…”
Get full text

Prophylactic cranial irradiation versus observation in patients with extensive-disease small-cell lung cancer: a multicentre, randomised, open-label, phase 3 trial by Takahashi, Toshiaki, MD, Yamanaka, Takeharu, Prof, Seto, Takashi, MD, Harada, Hideyuki, MD, Nokihara, Hiroshi, MD, Saka, Hideo, MD, Nishio, Makoto, MD, Kaneda, Hiroyasu, MD, Takayama, Koichi, MD, Ishimoto, Osamu, MD, Takeda, Koji, MD, Yoshioka, Hiroshige, MD, Tachihara, Motoko, MD, Sakai, Hiroshi, MD, Goto, Koichi, MD, Yamamoto, Nobuyuki, Prof

“…Summary Background Results from a previous phase 3 study suggested that prophylactic cranial irradiation reduces the incidence of symptomatic brain metastases…”
Get full text

Erlotinib alone or with bevacizumab as first-line therapy in patients with advanced non-squamous non-small-cell lung cancer harbouring EGFR mutations (JO25567): an open-label, randomised, multicentre, phase 2 study by Seto, Takashi, MD, Kato, Terufumi, MD, Nishio, Makoto, MD, Goto, Koichi, MD, Atagi, Shinji, MD, Hosomi, Yukio, MD, Yamamoto, Noboru, MD, Hida, Toyoaki, MD, Maemondo, Makoto, MD, Nakagawa, Kazuhiko, Prof, Nagase, Seisuke, MD, Okamoto, Isamu, MD, Yamanaka, Takeharu, PhD, Tajima, Kosei, MSc, Harada, Ryosuke, BS, Fukuoka, Masahiro, MD, Yamamoto, Nobuyuki, Prof

“…Summary Background With use of EGFR tyrosine-kinase inhibitor monotherapy for patients with activating EGFR mutation-positive non-small-cell lung cancer…”
Get full text

Crizotinib can overcome acquired resistance to CH5424802: is amplification of the MET gene a key factor? by Gouji, Toyokawa, Takashi, Seto, Mitsuhiro, Takenoyama, Yukito, Ichinose

Get more information

Single-arm, multicentre, phase II trial of nivolumab for unresectable or recurrent thymic carcinoma: PRIMER study by Katsuya, Yuki, Horinouchi, Hidehito, Seto, Takashi, Umemura, Shigeki, Hosomi, Yukio, Satouchi, Miyako, Nishio, Makoto, Kozuki, Toshiyuki, Hida, Toyoaki, Sukigara, Tamie, Nakamura, Kenichi, Kuchiba, Aya, Ohe, Yuichiro

“…Thymic carcinoma (TC) is a rare cancer with a poor prognosis and limited treatment options, especially after relapse. In this open-label, two-stage,…”
Get full text

Randomized Phase III Study of Pemetrexed Plus Cisplatin Versus Vinorelbine Plus Cisplatin for Completely Resected Stage II to IIIA Nonsquamous Non-Small-Cell Lung Cancer by Kenmotsu, Hirotsugu, Yamamoto, Nobuyuki, Yamanaka, Takeharu, Yoshiya, Katsuo, Takahashi, Toshiaki, Ueno, Tsuyoshi, Goto, Koichi, Daga, Haruko, Ikeda, Norihiko, Sugio, Kenji, Seto, Takashi, Toyooka, Shinichi, Date, Hiroshi, Mitsudomi, Tetsuya, Okamoto, Isamu, Yokoi, Kohei, Saka, Hideo, Okamoto, Hiroaki, Takiguchi, Yuichi, Tsuboi, Masahiro

“…To evaluate the efficacy of pemetrexed plus cisplatin versus vinorelbine plus cisplatin as postoperative adjuvant chemotherapy in patients with pathologic…”
Get full text

Final progression-free survival results from the J-ALEX study of alectinib versus crizotinib in ALK-positive non-small-cell lung cancer by Nakagawa, Kazuhiko, Hida, Toyoaki, Nokihara, Hiroshi, Morise, Masahiro, Azuma, Koichi, Kim, Young Hak, Seto, Takashi, Takiguchi, Yuichi, Nishio, Makoto, Yoshioka, Hiroshige, Kumagai, Toru, Hotta, Katsuyuki, Watanabe, Satoshi, Goto, Koichi, Satouchi, Miyako, Kozuki, Toshiyuki, Koyama, Ryo, Mitsudomi, Tetsuya, Yamamoto, Nobuyuki, Asakawa, Takashi, Hayashi, Morihiko, Hasegawa, Wakako, Tamura, Tomohide

“…•Final PFS data and second pre-planned interim analysis of OS and safety from J-ALEX.•Sustained improvement in IRF-assessed PFS demonstrated with…”
Get full text

CH5424802 (RO5424802) for patients with ALK -rearranged advanced non-small-cell lung cancer (AF-001JP study): a single-arm, open-label, phase 1–2 study by Seto, Takashi, MD, Kiura, Katsuyuki, Prof, Nishio, Makoto, MD, Nakagawa, Kazuhiko, Prof, Maemondo, Makoto, MD, Inoue, Akira, MD, Hida, Toyoaki, MD, Yamamoto, Nobuyuki, MD, Yoshioka, Hiroshige, MD, Harada, Masao, MD, Ohe, Yuichiro, MD, Nogami, Naoyuki, MD, Takeuchi, Kengo, MD, Shimada, Tadashi, MS, Tanaka, Tomohiro, MS, Tamura, Tomohide, Dr

“…Summary Background Currently, crizotinib is the only drug that has been approved for treatment of ALK -rearranged non-small-cell lung cancer (NSCLC). We aimed…”
Get full text

Afatinib versus cisplatin plus pemetrexed in Japanese patients with advanced non‐small cell lung cancer harboring activating EGFR mutations: Subgroup analysis of LUX‐Lung 3 by Kato, Terufumi, Yoshioka, Hiroshige, Okamoto, Isamu, Yokoyama, Akira, Hida, Toyoaki, Seto, Takashi, Kiura, Katsuyuki, Massey, Dan, Seki, Yoko, Yamamoto, Nobuyuki

“…In LUX‐Lung 3, afatinib significantly improved progression‐free survival (PFS) versus cisplatin/pemetrexed in EGFR mutation‐positive lung adenocarcinoma…”
Get full text

Spotlight on lorlatinib and its potential in the treatment of NSCLC: the evidence to date by Akamine, Takaki, Toyokawa, Gouji, Tagawa, Tetsuzo, Seto, Takashi

“…The identification of anaplastic lymphoma kinase ( ), an oncogenetic driver mutation, in lung cancer has paved the way for a new era in the treatment of…”
Get full text

Vandetanib in patients with previously treated RET -rearranged advanced non-small-cell lung cancer (LURET): an open-label, multicentre phase 2 trial by Yoh, Kiyotaka, Dr, Seto, Takashi, MD, Satouchi, Miyako, MD, Nishio, Makoto, MD, Yamamoto, Noboru, MD, Murakami, Haruyasu, MD, Nogami, Naoyuki, MD, Matsumoto, Shingo, MD, Kohno, Takashi, PhD, Tsuta, Koji, Prof, Tsuchihara, Katsuya, MD, Ishii, Genichiro, MD, Nomura, Shogo, MSc, Sato, Akihiro, MD, Ohtsu, Atsushi, MD, Ohe, Yuichiro, MD, Goto, Koichi, MD

“…Summary Background RET rearrangements are rare oncogenic alterations in non-small-cell lung cancer (NSCLC). Vandetanib is a multitargeted tyrosine kinase…”
Get full text

Gefitinib versus cisplatin plus docetaxel in patients with non-small-cell lung cancer harbouring mutations of the epidermal growth factor receptor (WJTOG3405): an open label, randomised phase 3 trial by Mitsudomi, Tetsuya, Dr, Morita, Satoshi, Prof, Yatabe, Yasushi, MD, Negoro, Shunichi, MD, Okamoto, Isamu, MD, Tsurutani, Junji, MD, Seto, Takashi, MD, Satouchi, Miyako, MD, Tada, Hirohito, MD, Hirashima, Tomonori, MD, Asami, Kazuhiro, MD, Katakami, Nobuyuki, MD, Takada, Minoru, Prof, Yoshioka, Hiroshige, MD, Shibata, Kazuhiko, MD, Kudoh, Shinzoh, MD, Shimizu, Eiji, Prof, Saito, Hiroshi, MD, Toyooka, Shinichi, MD, Nakagawa, Kazuhiko, Prof, Fukuoka, Masahiro, Prof

“…Summary Background Patients with non-small-cell lung cancer harbouring mutations in the epidermal growth factor receptor ( EGFR ) gene respond well to the…”
Get full text

The Role of Radiotherapy in the Treatment of Small-Cell Lung Cancer by Nosaki, Kaname, Seto, Takashi

“…Opinion Statement The standard therapy for limited disease small cell lung cancer (LD-SCLC) is concurrent chemoradiotherapy and prophylactic cranial…”
Get full text

Plerixafor stem cell mobilization in Japanese children: A post‐marketing study by Goto, Hiroaki, Kanamori, Rie, Nishina, Satoshi, Seto, Takashi

“…Background Plerixafor is approved in Japan for hematopoietic stem cell mobilization prior to autologous transplant, but limited data are available on the use…”
Get full text

Real world treatment and outcomes in EGFR mutation-positive non-small cell lung cancer: Long-term follow-up of a large patient cohort by Okamoto, Isamu, Morita, Satoshi, Tashiro, Naoki, Imamura, Fumio, Inoue, Akira, Seto, Takashi, Yamamoto, Nobuyuki, Ohe, Yuichiro, Nakagawa, Kazuhiko, Fukuoka, Masahiro

“…•We conducted a real-world survival analysis of EGFR mutation-positive NSCLC.•This study provides long-term follow-up data on a large patient group.•Patients…”
Get full text

Combined chemotherapy with cisplatin, etoposide, and irinotecan versus topotecan alone as second-line treatment for patients with sensitive relapsed small-cell lung cancer (JCOG0605): a multicentre, open-label, randomised phase 3 trial by Goto, Koichi, Dr, Ohe, Yuichiro, MD, Shibata, Taro, MSc, Seto, Takashi, MD, Takahashi, Toshiaki, MD, Nakagawa, Kazuhiko, Prof, Tanaka, Hiroshi, MD, Takeda, Koji, MD, Nishio, Makoto, MD, Mori, Kiyoshi, MD, Satouchi, Miyako, MD, Hida, Toyoaki, MD, Yoshimura, Naruo, MD, Kozuki, Toshiyuki, MD, Imamura, Fumio, MD, Kiura, Katsuyuki, Prof, Okamoto, Hiroaki, MD, Sawa, Toshiyuki, MD, Tamura, Tomohide, MD

“…Summary Background Etoposide and irinotecan are key drugs in the treatment of small-cell lung cancer. We did this study to investigate whether combined…”
Get full text

Capmatinib in Japanese patients with MET exon 14 skipping–mutated or MET‐amplified advanced NSCLC: GEOMETRY mono‐1 study by Seto, Takashi, Ohashi, Kadoaki, Sugawara, Shunichi, Nishio, Makoto, Takeda, Masayuki, Aoe, Keisuke, Moizumi, Sanae, Nomura, Satoshi, Tajima, Takeshi, Hida, Toyoaki

“…MET mutations leading to exon 14 skipping (METΔex14) are strong molecular drivers for non–small‐cell lung cancer (NSCLC). Capmatinib is a highly potent,…”
Get full text

Phase II study of ceritinib in alectinib‐pretreated patients with anaplastic lymphoma kinase‐rearranged metastatic non‐small‐cell lung cancer in Japan: ASCEND‐9 by Hida, Toyoaki, Seto, Takashi, Horinouchi, Hidehito, Maemondo, Makoto, Takeda, Masayuki, Hotta, Katsuyuki, Hirai, Fumihiko, Kim, Young Hak, Matsumoto, Shingo, Ito, Masayuki, Ayukawa, Koichi, Tokushige, Kota, Yonemura, Masataka, Mitsudomi, Testuya, Nishio, Makoto

“…Clinical experience of ceritinib in patients who progressed on alectinib is limited. In this prospective phase II study, we evaluated the activity of ceritinib…”
Get full text

Co-expression of IDO1 and PD-L1 in lung squamous cell carcinoma: Potential targets of novel combination therapy by Takada, Kazuki, Kohashi, Kenichi, Shimokawa, Mototsugu, Haro, Akira, Osoegawa, Atsushi, Tagawa, Tetsuzo, Seto, Takashi, Oda, Yoshinao, Maehara, Yoshihiko

“…•We examined the clinical significance of IDO1/PD-L1 co-expression in lung SCC.•IDO1 expression was significantly associated with PD-L1 expression.•IDO1/PD-L1…”
Get full text

Identification of the Best Prognostic Marker Among Immunonutritional Parameters Using Serum C-Reactive Protein and Albumin in Non-Small Cell Lung Cancer by Matsubara, Taichi, Takamori, Shinkichi, Haratake, Naoki, Fujishita, Takatoshi, Toyozawa, Ryo, Ito, Kensaku, Shimokawa, Mototsugu, Yamaguchi, Masafumi, Seto, Takashi, Okamoto, Tatsuro

“…Background Three immune-nutritional parameters exist for malignant tumors using serum C-reactive protein (CRP) and albumin: the Glasgow prognostic score (GPS),…”
Get full text